Last reviewed · How we verify

Glycoprotein IIb/IIIa inhibitors

University of Luebeck · FDA-approved active Small molecule

Glycoprotein IIb/IIIa inhibitors is a Glycoprotein IIb/IIIa inhibitor Small molecule drug developed by University of Luebeck. It is currently FDA-approved for Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction), Percutaneous coronary intervention in patients at high risk for ischemic complications.

Glycoprotein IIb/IIIa inhibitors block the final common pathway of platelet aggregation by preventing fibrinogen binding to activated platelets.

Glycoprotein IIb/IIIa inhibitors block the final common pathway of platelet aggregation by preventing fibrinogen binding to activated platelets. Used for Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction), Percutaneous coronary intervention in patients at high risk for ischemic complications.

At a glance

Generic nameGlycoprotein IIb/IIIa inhibitors
SponsorUniversity of Luebeck
Drug classGlycoprotein IIb/IIIa inhibitor
TargetGlycoprotein IIb/IIIa receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

These agents competitively inhibit the glycoprotein IIb/IIIa receptor on the platelet surface, which is the final step in platelet aggregation regardless of the initial stimulus. By blocking fibrinogen and other adhesive molecules from cross-linking platelets, they prevent thrombus formation. This class is used primarily in acute coronary syndromes to reduce ischemic complications during percutaneous coronary intervention.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Glycoprotein IIb/IIIa inhibitors

What is Glycoprotein IIb/IIIa inhibitors?

Glycoprotein IIb/IIIa inhibitors is a Glycoprotein IIb/IIIa inhibitor drug developed by University of Luebeck, indicated for Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction), Percutaneous coronary intervention in patients at high risk for ischemic complications.

How does Glycoprotein IIb/IIIa inhibitors work?

Glycoprotein IIb/IIIa inhibitors block the final common pathway of platelet aggregation by preventing fibrinogen binding to activated platelets.

What is Glycoprotein IIb/IIIa inhibitors used for?

Glycoprotein IIb/IIIa inhibitors is indicated for Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction), Percutaneous coronary intervention in patients at high risk for ischemic complications.

Who makes Glycoprotein IIb/IIIa inhibitors?

Glycoprotein IIb/IIIa inhibitors is developed and marketed by University of Luebeck (see full University of Luebeck pipeline at /company/university-of-luebeck).

What drug class is Glycoprotein IIb/IIIa inhibitors in?

Glycoprotein IIb/IIIa inhibitors belongs to the Glycoprotein IIb/IIIa inhibitor class. See all Glycoprotein IIb/IIIa inhibitor drugs at /class/glycoprotein-iib-iiia-inhibitor.

What development phase is Glycoprotein IIb/IIIa inhibitors in?

Glycoprotein IIb/IIIa inhibitors is FDA-approved (marketed).

What are the side effects of Glycoprotein IIb/IIIa inhibitors?

Common side effects of Glycoprotein IIb/IIIa inhibitors include Thrombocytopenia, Bleeding, Hypotension, Bradycardia.

What does Glycoprotein IIb/IIIa inhibitors target?

Glycoprotein IIb/IIIa inhibitors targets Glycoprotein IIb/IIIa receptor and is a Glycoprotein IIb/IIIa inhibitor.

Related